| Carlyle Senior Care Of Fountain Inn | |
| 501 Gulliver St, Fountain Inn, South Carolina 29644 | |
| (864) 862-2554 | |
| Name | Carlyle Senior Care Of Fountain Inn |
|---|---|
| Location | 501 Gulliver St, Fountain Inn, South Carolina |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 60 |
| Occupancy Rate | 72.67% |
| Medicare ID (CCN) | 425168 |
| Legal Business Name | Carlyle Senior Care Of Fountain Inn, Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1417961715 |
| Organization Name | CARLYLE SENIOR CARE OF FOUNTAIN INN,LLC |
| Doing Business As | FOUNTAIN INN NURSING HOME |
| Address | 501 Gulliver St, Fountain Inn, SC 29644 |
| Phone Number | 864-862-2554 |
News Archive
Biogen Idec and Swedish Orphan Biovitrum AB (publ) today presented new findings for their long-lasting recombinant factor IX candidate ALPROLIX for hemophilia B at the XXIV International Society on Thrombosis and Haemostasis Congress in Amsterdam, The Netherlands.
A research team from Massachusetts Eye and Ear and the Massachusetts Institute of Technology has shown that immune cells in the eye that developed in response to early exposure to bacteria are a key contributor to progressive vision loss from glaucoma, the second leading cause of irreversible blindness in the world.
In experiments with fruit flies, Johns Hopkins researchers have discovered how a key light-detecting molecule in the eye moves in response to changes in light intensity.
In the largest study of its kind, researchers from Mount Sinai School of Medicine have discovered five new genetic mutations associated with Crohn's disease in Jews of Eastern European descent, also known as Ashkenazi Jews.
› Verified 3 days ago
| NPI Number | 1912630120 |
| Organization Name | FOUNTAIN INN HEALTHCARE, LLC |
| Address | 501 Gulliver St, Fountain Inn, SC 29644 |
| Phone Number | 864-862-2554 |
News Archive
Biogen Idec and Swedish Orphan Biovitrum AB (publ) today presented new findings for their long-lasting recombinant factor IX candidate ALPROLIX for hemophilia B at the XXIV International Society on Thrombosis and Haemostasis Congress in Amsterdam, The Netherlands.
A research team from Massachusetts Eye and Ear and the Massachusetts Institute of Technology has shown that immune cells in the eye that developed in response to early exposure to bacteria are a key contributor to progressive vision loss from glaucoma, the second leading cause of irreversible blindness in the world.
In experiments with fruit flies, Johns Hopkins researchers have discovered how a key light-detecting molecule in the eye moves in response to changes in light intensity.
In the largest study of its kind, researchers from Mount Sinai School of Medicine have discovered five new genetic mutations associated with Crohn's disease in Jews of Eastern European descent, also known as Ashkenazi Jews.
› Verified 3 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Biogen Idec and Swedish Orphan Biovitrum AB (publ) today presented new findings for their long-lasting recombinant factor IX candidate ALPROLIX for hemophilia B at the XXIV International Society on Thrombosis and Haemostasis Congress in Amsterdam, The Netherlands.
A research team from Massachusetts Eye and Ear and the Massachusetts Institute of Technology has shown that immune cells in the eye that developed in response to early exposure to bacteria are a key contributor to progressive vision loss from glaucoma, the second leading cause of irreversible blindness in the world.
In experiments with fruit flies, Johns Hopkins researchers have discovered how a key light-detecting molecule in the eye moves in response to changes in light intensity.
In the largest study of its kind, researchers from Mount Sinai School of Medicine have discovered five new genetic mutations associated with Crohn's disease in Jews of Eastern European descent, also known as Ashkenazi Jews.
› Verified 3 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 19.44 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 7.27 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 65.22 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.73 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.81 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 10.37 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 96.06 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 5.41 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 18.8 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 18.84 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 14.78 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.86 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 55.86 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 94.38 | 82.93 |
News Archive
Biogen Idec and Swedish Orphan Biovitrum AB (publ) today presented new findings for their long-lasting recombinant factor IX candidate ALPROLIX for hemophilia B at the XXIV International Society on Thrombosis and Haemostasis Congress in Amsterdam, The Netherlands.
A research team from Massachusetts Eye and Ear and the Massachusetts Institute of Technology has shown that immune cells in the eye that developed in response to early exposure to bacteria are a key contributor to progressive vision loss from glaucoma, the second leading cause of irreversible blindness in the world.
In experiments with fruit flies, Johns Hopkins researchers have discovered how a key light-detecting molecule in the eye moves in response to changes in light intensity.
In the largest study of its kind, researchers from Mount Sinai School of Medicine have discovered five new genetic mutations associated with Crohn's disease in Jews of Eastern European descent, also known as Ashkenazi Jews.
› Verified 3 days ago
Carlyle Senior Care Of Fountain Inn Location: 501 Gulliver St, Fountain Inn, South Carolina 29644 Phone: (864) 862-2554 |